Publications
Detailed Information
The anti-inflammatory drug Diclofenac retains anti-listerial activity in vivo
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Dutta, N.K. | - |
dc.contributor.author | Mazumdar, K. | - |
dc.contributor.author | Seok, S.H. | - |
dc.contributor.author | Park, Jae Hak | - |
dc.date.accessioned | 2009-08-31T23:41:35Z | - |
dc.date.available | 2009-08-31T23:41:35Z | - |
dc.date.issued | 2008 | - |
dc.identifier.citation | Lett Appl Microbiol 47, 106-111 | en |
dc.identifier.issn | 0266-8254 | - |
dc.identifier.uri | https://hdl.handle.net/10371/8294 | - |
dc.description.abstract | Aims: The interactions between nonsteroidal anti-inflammatory drugs (NSAID) and Listeria monocytogenes have not been sufficiently documented to date. The aim of this study was to investigate the possible effects of Diclofenac (Dc) in a murine listerial infection model. Methods and Results: Dc was administered orally at 2·5 μg g−1 to female albino strain of laboratory mouse (BALB/c) thrice postinfection (1 × 108 CFU ml−1 oral challenge with L. monocytogenes ATCC 51774), which resulted in significantly ( P < 0·01) reduced bacterial counts in liver and spleen, decreased (10-fold, P < 0·05) hepatic colonization and necrosis, and caused up-regulation of the expression of inflammatory cytokines (interferon-γ, interleukin-1β, tumour necrosis factor-α), compared with drug-free control. Conclusions: Dc may be useful as a promising adjuvant to the existing therapies in controlling systemic listerial infection. Further, quantitative structure–activity relationship studies might contribute in manipulating it as a lead compound for the synthesis of new, more effective nonantibiotics, perhaps, devoid of side-effects that could be recommended as a compassionate therapy for listeriosis. Significance and Impact of the study: This is the first in vivo study designed to evaluate the antilisterial effect of the NSAID Dc with special emphasis on the immunological mechanism of action of the drug. | en |
dc.description.sponsorship | This work was supported by grants provided by the Korea
Research Foundation (KRF-005-E00077) and Brain Korea 21 project, South Korea. We appreciate the assistance of Min-Won Baek, Dong-Jae Kim, Yi-Rang Na, Sung-Hoon Park, Hyun-Kyoung Lee and Byoung-Hee Lee in this study. Ethical approval: all animal experiments were carried out based on the guidelines and regulations for the care and use of laboratory animals of Seoul National University (approval no. SNU 060816-7). | en |
dc.language.iso | en | - |
dc.publisher | Wiley-Blackwell | en |
dc.subject | Diclofenac | en |
dc.subject | in vivo activity | en |
dc.subject | Listeria monocytogenes | en |
dc.title | The anti-inflammatory drug Diclofenac retains anti-listerial activity in vivo | en |
dc.type | Article | en |
dc.contributor.AlternativeAuthor | 박재학 | - |
dc.identifier.doi | 10.1111/j.1472-765X.2008.02391.x | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.